Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page shows a 403 Forbidden error instead of the study record details, blocking access to the study content. This indicates the study information is not currently accessible on the page.
    Difference
    17%
    Check dated 2026-09-23T00:59:49.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.6 to v3.7.0 on the page, indicating a version update rather than a change to the study details or eligibility information.
    Difference
    0.1%
    Check dated 2026-09-16T00:15:40.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    Revision indicator on the page was updated to v3.6.6, replacing the previous v3.6.5.
    Difference
    0.1%
    Check dated 2026-09-01T19:32:36.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The revision label was updated from v3.6.4 to v3.6.5, indicating a platform update. The study details and user-facing content remain unchanged.
    Difference
    0.1%
    Check dated 2026-08-11T14:50:42.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The page shows a new revision label, updating from v3.6.3 to v3.6.4, indicating a deployment of a new build. The underlying study information and content remain unchanged.
    Difference
    0.1%
    Check dated 2026-07-28T05:57:30.000Z thumbnail image
  7. Check
    82 days ago
    Change Detected
    Summary
    The revision label in the page footer was updated from v3.6.2 to v3.6.3, signaling a minor maintenance update to the site.
    Difference
    0.1%
    Check dated 2026-07-06T15:48:44.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.